Key result
Baseline vascular measurements alone accounted for 12-month predictions (optimism-corrected R-squared 0.652 for baPWV, 0.726 for cIMT), while Fibulin-1 was not retained in primary LASSO models.
Why the study?
Predicting longitudinal vascular measurements in patients with coexisting obstructive sleep apnea and hypertension may help guide future research on vascular risk assessment, motivating the development and internal validation of predictive models for 12-month brachial-ankle pulse wave velocity and carotid intima-media thickness.
Do baseline clinical candidates and plasma Fibulin-1 add predictive value beyond baseline vascular measurements for 12-month continuous baPWV and cIMT in patients with mild-to-moderate OSA and hypertension?
Cohort (n=360)
Readers blinded to baseline cIMT at 12 months; operator and laboratory blinding not documented/verified
No
Do baseline clinical candidates and plasma Fibulin-1 add predictive value beyond baseline vascular measurements for 12-month continuous baPWV and cIMT in patients with mild-to-moderate OSA and hypertension?
In patients with mild-to-moderate OSA and hypertension, baseline vascular measurements account for nearly all predictive value for 12-month baPWV and cIMT, whereas candidate biomarkers like Fibulin-1 add no verified predictive contribution to continuous outcomes.
Answers are grounded in this paper and cite their sources.
Baseline vascular measures suffice for 12-month prediction; leaves open Fibulin-1's incremental value in prospective cohorts.
Predicting longitudinal vascular measurements in patients with obstructive sleep apnea (OSA) and hypertension may help guide future research on vascular risk assessment. We developed and internally validated models for continuous 12-month brachial-ankle pulse wave velocity (baPWV) and carotid intima-media thickness (cIMT), accounting for baseline vascular status. This retrospective cohort included 360 patients with mild-to-moderate OSA and hypertension at one hospital in China. Separate least absolute shrinkage and selection operator models included the corresponding baseline vascular measure without penalization and 34 penalized baseline candidates. Ten-fold cross-validation selected the penalty, and 1,000 bootstrap samples repeated model development and internal evaluation. A composite increase in baPWV of at least 100 cm/s or cIMT of at least 0.1 mm was examined as an exploratory secondary outcome. The full-data primary models retained only the corresponding baseline vascular measurement. Optimism-corrected R-squared values were 0.652 for baPWV and 0.726 for cIMT. Fibulin-1 was not retained in either full-data primary model. In exploratory analyses of a measurement-sensitive binary composite, allowing Fibulin-1 increased the corrected area under the curve by 0.167 in paired resampling. Because original assay quality-control records were unavailable, this apparent increment cannot establish a reproducible biomarker contribution. Baseline vascular measurements accounted for most of the predictive information in the primary models. Fibulin-1 findings remain exploratory because the biomarker’s apparent contribution to the binary endpoint is sensitive to outcome measurement and the assay cannot be independently audited. These internally validated models are not ready for clinical use; standardized measurement and independent validation are needed.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) conducted a cohort in Coexisting mild-to-moderate obstructive sleep apnea and hypertension (n=360). Penalized LASSO prediction models using baseline vascular measurements (baPWV, cIMT) and 34 candidate predictors including plasma Fibulin-1 was evaluated on Continuous 12-month brachial-ankle pulse wave velocity (baPWV) and carotid intima-media thickness (cIMT) (Optimism-corrected R-squared 0.652 for baPWV and 0.726 for cIMT (retaining only baseline vascular measurements; Fibulin-1 coefficient 0)). Baseline vascular measurements alone accounted for 12-month predictions (optimism-corrected R-squared 0.652 for baPWV, 0.726 for cIMT), while Fibulin-1 was not retained in primary LASSO models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: